Peter Pattison

Peter Pattison currently serves as the President of Interventional Oncology at Boston Scientific, having joined through the acquisition of BTG plc in August 2019. In addition, Peter is a member of the Board of Directors at the Centre for Probe Development and Commercialization since June 2021. Prior to this, Peter was the Head of Interventional Oncology at BTG plc, leading a division with a business unit worth over $200 million, and held various leadership roles at Nordion, including General Manager of TheraSphere. Peter's earlier experience includes senior positions at Ricerca Biosciences and MDS Pharma Services, where responsibilities included overseeing substantial P&L operations and development projects. Peter's educational background includes a Bachelor of Science in Biochemistry and an MBA, both obtained from Queen's University.